L&K Biomed Participates in Chest Wall International Group (CWIG) Conference

L&K Biomed's U.S. subsidiary, Aegis Meditech Inc., announced on September 19 that it actively promoted its pectus excavatum implant, "Pectus," at the Chest Wall International Group (CWIG) conference held in Nagano, Japan, starting from September 17.

The Chest Wall International Group is a prestigious international academic conference held annually, where thoracic surgeons, pediatric surgeons, and plastic surgeons from around the world gather to share research on the treatment of congenital chest wall deformities (such as pectus excavatum and pectus carinatum) and chest wall resection and reconstruction procedures. L&K Biomed has participated for two consecutive years, further strengthening its presence in the global market.

Aegis Meditech, the U.S. subsidiary of L&K Biomed, participated with an exclusive booth and actively promoted the "Pectus" implant for pectus excavatum through meetings with hospital medical staff and representatives.

In cooperation with Solve, the leading medical device distributor for pectus excavatum implants in Japan, the company provided participating medical professionals with the opportunity to experience the product firsthand. Solve organized an educational dry lab session at the event, allowing attendees to practice assembling and disassembling the main components of the "Pectus" device and learn its usage procedures.

A representative from L&K Biomed stated, "It was a great opportunity to receive direct feedback on the product at the event. We plan to incorporate expert opinions to further upgrade the product in the future."

Completed last year, the "Pectus" implant is a next-generation device developed by integrating clinical advice from leading surgeons in the United States and China with L&K's expertise in spinal implant development. Designed as an integrated system to accommodate a variety of surgical techniques, it reduces surgical difficulty and maximizes convenience.

"Pectus" received FDA approval in the United States in April and completed its application for approval in Thailand at the end of June. The product is currently being stably supplied in the U.S. market amid high interest and demand. Sales in the first half of this year have already surpassed last year's annual sales.

A representative from L&K Biomed explained, "The fact that medical professionals at the conference were able to experience the product firsthand and gave positive evaluations served as proof of our global competitiveness."

This content was produced with the assistance of AI translation services.